{
    "id": 1181,
    "fullName": "BRCA1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRCA1 mutant indicates an unspecified mutation in the BRCA1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 672,
        "geneSymbol": "BRCA1",
        "terms": [
            "BRCA1",
            "BRCAI",
            "BRCC1",
            "BROVCA1",
            "FANCS",
            "IRIS",
            "PNCA4",
            "PPP1R53",
            "PSCP",
            "RNF53"
        ]
    },
    "variant": "mutant",
    "createDate": "07/28/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17704,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "FOLFIRINOX is included in guidelines as a first-line therapy for advanced or metastatic pancreatic adenocarcinoma patients with BRCA1 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1903,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "FOLFIRINOX|FOLFOXIRI"
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11980,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-290 treatment resulted in improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 2947,
                "therapyName": "Pamiparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9945,
                    "pubMedId": null,
                    "title": "Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17485,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines for triple-receptor negative breast cancer patients with BRCA mutations who were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2869,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative BRCA1-mutant breast cancer cell lines under hypoxic conditions (PMID: 25193512).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17274,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BAY 1895344 treatment resulted in stable disease lasting over 10 months in a patient with BRCA1-mutant, Lynparza (olaparib)-resistant ovarian cancer (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 5962,
                "therapyName": "BAY1895344",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15304,
                    "pubMedId": null,
                    "title": "First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.",
                    "url": "https://abstracts.asco.org/239/AbstView_239_265503.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD2461 inhibited the growth of BRCA1 mutant breast cancer cells in culture (PMID: 27550455).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 2542,
                "therapyName": "AZD2461",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6793,
                    "pubMedId": 27550455,
                    "title": "The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550455"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13146,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10991,
                    "pubMedId": null,
                    "title": "A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_3/mdy048.003/4917515"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6745,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19) and a disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5806,
                    "pubMedId": null,
                    "title": "RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.",
                    "url": "http://meetinglibrary.asco.org/content/166810-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2193,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) induced DNA damage and decreased tumor growth in an intracranial human BRCA-mutant triple-negative breast cancer cell line xenograft model, but did not provide a significant survival benefit over Paraplatin (carboplatin) alone (PMID: 25824335).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 2704,
                "therapyName": "Carboplatin + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2753,
                    "pubMedId": 25824335,
                    "title": "Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25824335"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20814,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) treatment resulted in a partial response with a median response duration of 387 days in 40% (8/20) of patients with BRCA1- or BRCA2-mutated ovarian or primary peritoneal cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 1725,
                "name": "peritoneum cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12849,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NMS-P118 treatment resulted in antitumor activity in BRCA1 mutant breast cancer xenograft models, demonstrating tumor growth inhibition and induction of a complete response (PMID: 26222319).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 4422,
                "therapyName": "NMS-P118",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6203,
                    "pubMedId": 26222319,
                    "title": "Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26222319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17711,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline BRCA1/2 mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17475,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines for breast cancer patients with BRCA mutations who progressed on endocrine therapy and were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1051,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA1 mutations, with an objective response rate of 50% (9/18) in the maximum tolerated dose cohort and 19% (3/16) in the lower dose cohort (PMID: 20609467).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 770,
                    "pubMedId": 20609467,
                    "title": "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20609467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20812,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) treatment resulted in a partial response with a median response duration of 387 days in 40% (8/20) of patients with BRCA1- or BRCA2-mutated ovarian or primary peritoneal cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9004,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NOVA), maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299; NCT01847274).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6850,
                    "pubMedId": 27717299,
                    "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717299"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7478,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, Xgeva (denosumab) inhibited cell proliferation in normal breast tissues of BRCA1 mutation carriers, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1198,
                "therapyName": "Denosumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6366,
                    "pubMedId": 27322743,
                    "title": "RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27322743"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7525,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 3314,
                "therapyName": "Irinotecan + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6398,
                    "pubMedId": 26842236,
                    "title": "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26842236"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11195,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17488,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines for triple-receptor negative breast cancer patients with BRCA mutations who were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11194,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talzenna (talazoparib) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation (n=9) resulted in a clinical benefit rate of 56% and a median progression-free survival of 20.4 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6857,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) was well-tolerated and demonstrated preliminary efficacy in advanced solid tumor patients, including partial responses in 50% (2/4) of breast cancer patients carrying BRCA1 or BRCA2 mutations (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10817,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-290 inhibited PARylation and demonstrated anti-tumor activity in cell line xenograft models of breast cancer harboring BRCA1 mutations (Cancer Res 2015; 75(15 Suppl): Abstract nr 1653).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 2947,
                "therapyName": "Pamiparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8853,
                    "pubMedId": null,
                    "title": "BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/1653.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6519,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=14/79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 4133,
                "therapyName": "ABT-767",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5681,
                    "pubMedId": null,
                    "title": "A STUDY OF ABT-767 IN ADVANCED SOLID TUMORS WITH BRCA 1 AND BRCA 2 MUTATIONS AND HIGH GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER",
                    "url": "http://annonc.oxfordjournals.org/content/25/suppl_4/iv150.2.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13732,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline BRCA1/2 mutations are associated with increased risk of developing and early onset of pancreatic cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6874,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888), in combination with Platinol (cisplatin) and Navelbine (vinorelbine), resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 4286,
                "therapyName": "Cisplatin + Veliparib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5936,
                    "pubMedId": 26801247,
                    "title": "Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801247"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12602,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ARIEL3), Rubraca (rucaparib) treatment resulted in significantly improved progression-free survival compared to placebo (16.6 vs 5.4 months, HR=0.23, p=0.0001) in patients with BRCA-mutant, platinum-sensitive ovarian cancer (PMID: 28916367; NCT01968213).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10475,
                    "pubMedId": 28916367,
                    "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28916367"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8863,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6778,
                    "pubMedId": 27002934,
                    "title": "Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27002934"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6858,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Talazoparib (BMN-673) was well-tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including objective responses in 33% (2/6) of breast cancer patients carrying BRCA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5875,
                    "pubMedId": null,
                    "title": "First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors",
                    "url": "http://meetinglibrary.asco.org/content/111725-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17478,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines for breast cancer patients with BRCA mutations who progressed on endocrine therapy and were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11193,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14) including one patient with a complete response and six patients with a partial response and a median progression free survival of 34.6 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17707,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Platinol (cisplatin), in combination with Gemzar (gemcitabine), is included in guidelines as a first-line therapy for advanced or metastatic pancreatic adenocarcinoma patients with BRCA1 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1467,
                "therapyName": "Cisplatin + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21195,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) and Avastin (bevacizumab) combination therapy is included in guidelines as maintenance therapy for ovarian cancer patients harboring germline or somatic BRCA1/2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 9297,
                "therapyName": "Bevacizumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20388,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (PAOLA-1) trial, addition of maintenance Lynparza (olaparib) to Avastin (bevacizumab) improved median progression-free survival (mPFS) compared to placebo (22.1 vs 16.6 mo, HR=0.59, p<0.001) in patients with advanced ovarian cancer receiving standard first-line therapy, mPFS was significantly improved (37.2 vs 17.7 mo, HR=0.33) in patients with tumors harboring homologous-recombination deficiency, including BRCA mutations (PMID: 31851799; NCT02477644).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 9297,
                "therapyName": "Bevacizumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17826,
                    "pubMedId": 31851799,
                    "title": "Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31851799"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6852,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 2704,
                "therapyName": "Carboplatin + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5878,
                    "pubMedId": null,
                    "title": "Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).",
                    "url": "http://meetinglibrary.asco.org/content/132155-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14033,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase III trial, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11433,
                    "pubMedId": 29191972,
                    "title": "Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29191972"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17380,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines as a maintenance therapy following response to a platinum-based therapy in ovarian cancer patients with BRCA mutations (ESMO Guidelines; PMID: 31046081).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15114,
                    "pubMedId": 31046081,
                    "title": "ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31046081"
                },
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6711,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",
            "molecularProfile": {
                "id": 23675,
                "profileName": "BRCA1 mut TP53 Y220C"
            },
            "therapy": {
                "id": 4253,
                "therapyName": "Carboplatin + VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5761,
                    "pubMedId": null,
                    "title": "Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_165738.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7479,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, Xgeva (denosumab) inhibited cell proliferation in 3D-organoid culture of PGR-positive human breast tissues harboring BRCA1 mutations, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743).",
            "molecularProfile": {
                "id": 25527,
                "profileName": "BRCA1 mut PGR pos"
            },
            "therapy": {
                "id": 1198,
                "therapyName": "Denosumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6366,
                    "pubMedId": 27322743,
                    "title": "RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27322743"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8441,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0917 treatment induced rapid decrease of Birc2 (cIAP-1) level, and resulted in complete response in an ovarian cancer patient harboring germline BRCA1 mutation, who remained disease-free for 18 months after discontinuing treatment (PMID: 27076626).",
            "molecularProfile": {
                "id": 26331,
                "profileName": "BIRC2 pos BRCA1 mut"
            },
            "therapy": {
                "id": 3639,
                "therapyName": "GDC-0917",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6658,
                    "pubMedId": 27076626,
                    "title": "A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076626"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9774,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of RAD51 in a BRCA1 mutant TNBC cell line demonstrated increased sensitivity to Lynparza (olaparib), resulting in decreased cell viability in culture and reduced tumor growth in cell line xenograft models (PMID: 28034904).",
            "molecularProfile": {
                "id": 27077,
                "profileName": "BRCA1 mut RAD51 dec exp"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7596,
                    "pubMedId": 28034904,
                    "title": "RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28034904"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11776,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in complete response in an ovarian cancer patient harboring a TP53 exon 7 mutation, and mutations in BRCA1, CCNE1, and MYC (PMID: 27998224).",
            "molecularProfile": {
                "id": 28239,
                "profileName": "BRCA1 mut CCNE1 mut MYC mut TP53 exon7"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11779,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224).",
            "molecularProfile": {
                "id": 28241,
                "profileName": "BRCA1 mut TP53 E298*"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human mammary epithelial cells with knockdown of GPBP1 and expressing a BRCA1 mutation demonstrated resistance to Talazoparib (BMN673) treatment in culture (PMID: 29669295).",
            "molecularProfile": {
                "id": 29576,
                "profileName": "BRCA1 mut GPBP1 dec exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11296,
                    "pubMedId": 29669295,
                    "title": "A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29669295"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13924,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1 mutant-positive triple-receptor negative breast cancer cells expressing PARP1 F44Mfs*50 and PARP1 M43Ifs*2 demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29872,
                "profileName": "BRCA1 mut PARP1 F44Lfs*2 PARP1 F44Mfs*50"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1 mutant-positive triple-receptor negative breast cancer cells expressing PARP1 F44Mfs*50, PARP1 F44Lfs*2, PARP1 M43Ifs*52, and PARP1 M43_D45del demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29873,
                "profileName": "BRCA1 mut PARP1 M43_D45del PARP1 M43Ifs*52 PARP1 F44Lfs*2 PARP1 F44Mfs*50"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian cancer cells harboring two BRCA1 mutations and expressing PARP1 K119_S120del demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29874,
                "profileName": "BRCA1 mut PARP1 K119_S120del"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13927,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian cancer cells harboring two BRCA1 mutations and expressing PARP1 Y848del and PARP1 Y848_K849del demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29875,
                "profileName": "BRCA1 mut PARP1 Y848_K849del PARP1 Y848del"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13928,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian cancer cells harboring two BRCA1 mutations and expressing PARP1 Y848_F851del demonstrated resistance to treatment with Talazoparib (BMN-673) in culture (PMID: 29748565).",
            "molecularProfile": {
                "id": 29876,
                "profileName": "BRCA1 mut PARP1 Y848_F851del"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11365,
                    "pubMedId": 29748565,
                    "title": "Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748565"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19859,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment induced tumor regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19861,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment inhibited tumor growth but did not induce regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19863,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1205,
            "profileName": "BRCA1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10545,
            "profileName": "BRCA1 mut ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23675,
            "profileName": "BRCA1 mut TP53 Y220C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25527,
            "profileName": "BRCA1 mut PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26331,
            "profileName": "BIRC2 pos BRCA1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27077,
            "profileName": "BRCA1 mut RAD51 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27913,
            "profileName": "BRCA1 mut ERBB2 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28239,
            "profileName": "BRCA1 mut CCNE1 mut MYC mut TP53 exon7",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28241,
            "profileName": "BRCA1 mut TP53 E298*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29576,
            "profileName": "BRCA1 mut GPBP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29872,
            "profileName": "BRCA1 mut PARP1 F44Lfs*2 PARP1 F44Mfs*50",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29873,
            "profileName": "BRCA1 mut PARP1 M43_D45del PARP1 M43Ifs*52 PARP1 F44Lfs*2 PARP1 F44Mfs*50",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29874,
            "profileName": "BRCA1 mut PARP1 K119_S120del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29875,
            "profileName": "BRCA1 mut PARP1 Y848_K849del PARP1 Y848del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29876,
            "profileName": "BRCA1 mut PARP1 Y848_F851del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34555,
            "profileName": "ATM wild-type BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34748,
            "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}